Intellia Therapeutics, Inc. NTLA
9.70 USD -0.85 (-8.06%)
At closeNov 13, 2026, 7:57 PM EST
9.80 +0.10 +1.03%
After hours · Nov 13, 7:57 PM ET
9.67 Day range 10.50
8.04 52-week range 17.84
- YTD
- +7.90%
- 1 year
- +11.88%
News
seekingalpha.com Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript Intellia Therapeutics, Inc. ( NTLA ) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE November 12, 2026 10:00 AM EST Company Participants Jason Fredette - Vice President of…
marketbeat.com Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears Intellia Therapeutics NASDAQ: NTLA presented additional clinical data and outlined launch plans for lonvo-z, its investigational one-time gene-editing treatment for hereditary angioedema, as the…
globenewswire.com Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026 CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
globenewswire.com Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
benzinga.com Intellia Therapeutics Q3 EPS $(0.91) Misses $(0.80) Estimate, Sales $7.163M Miss $10.461M Estimate Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.80) by 15.19 percent. This is a 1.09 percent increase over losses…
benzinga.com Intellia Therapeutics Completed Participant Enrollment In Its MAGNITUDE-2 Study Of ATTRv-PN Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the…